FDA Clears Tysabri For Limited Clinical Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Patients who had previously been receiving the multiple sclerosis therapy are now eligible to participate in Biogen Idec/Elan’s pending safety extension study.
You may also be interested in...
“Lax” MS Trial Entry Criteria Is A Threat To Patient Safety, Lancet Article Says
Authors calls for safeguards against inclusion of misdiagnosed patients in MS trials.
“Lax” MS Trial Entry Criteria Is A Threat To Patient Safety, Lancet Article Says
Authors calls for safeguards against inclusion of misdiagnosed patients in MS trials.
Tysabri To Go Before Advisory Committee On March 7
Committee discussion will include multiple sclerosis therapy’s proposed risk management plan and possible return to market.